Merck has secured the worldwide exclusive rights to PI-2301, an experimental drug for multiple sclerosis (MS).
The acquisition from Peptimmune Inc covers the development and commercialisation rights for the product which has just completed Phase 1b clinical trials.
Susan Herbert, Head of Global Portfolio Development at the Merck Serono division says the drug “could play a valuable role in the treatment of this debilitating disease”.
The second-generation peptide copolymer is believed to enhance the regulatory response of the immune system. Merck will now investigate the application of the product in autoimmune diseases as it progresses to Phase II clinical trials.
“Over the years we have continuously worked on developing innovative treatment options that meet the individual needs of people living with multiple sclerosis,” said Susan Herbert.